In the future, it will be necessary to extend the analysis of psoriasis-related SNPs to a largest cohort of oncological patients developing psoriasiform reactions to anti-PD-1, but also in a population successfully responding to the treatment, to identify differences in the genetic background of the patients. The gene discussed is PDCD1; the disease is psoriasis.